Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 15,685

Document Document Title
WO/2011/021678A1
Disclosed are: a fused heterocyclic compound having excellent medical activities including a p38 MAPK-inhibiting activity and a TNF-α production-inhibiting activity; a medicinal agent comprising the compound; and others. Specifically di...  
WO/2011/022491A1
This application describes methods of making and using physiological cysteine solutions useful for reversing a neuromuscular blockade caused by a cysteine-reversible neuromuscular blockade agent, that overcomes problems of cysteine preci...  
WO/2011/020874A1
The invention relates to methods for the treatment of Duchenne muscular dystrophy and to methods for determining the prognosis of a subject affected with Duchenne Muscular Dystrophy. More particularly, the present invention relates to a ...  
WO/2011/018588A2
The invention relates to FGF receptor-activating N-acyl octasaccharides having Formula (I), wherein: R1 is an O-alkyl group optionally replaced by one or more aryl or cycloalkyl groups, R2 is an OSO3- or hydroxyl group, R3 is an alkyl, c...  
WO/2011/019348A1
Disclosed are creatine β-alaninate, compositions and formulations containing same, and methods of use therefor.  
WO/2011/018587A2
The invention relates to FGF receptor-activating N-sulfate oligosaccharides having Formula (I), wherein R1, R4, R6, and R8 are –OSO3- or hydroxyl groups, R2 is an –O-alkyl group or a monosaccharide having Formula (II), R3 is a disaccha...  
WO/2011/016814A1
Disclosed are compounds such as 5α-androstane-3, 6, 17- trione, formulations comprising said compounds, and methods of use thereof to stimulate endogenous testosterone production and improve athletic performance and libido.  
WO/2011/016459A1
Disclosed is a compound which has serotonin 5-HT2C receptor activating activity. Specifically disclosed is a compound represented by formula (I) or a salt thereof. (In the formula, the symbols are as defined in the description.)  
WO/2011/013785A1
Disclosed are a compound represented by general formula [I], a pharmaceutically acceptable salt thereof or a solvate of the same, and medicinal use thereof for treating rejection in organ transplantation, graft-versus-host reaction after...  
WO/2011/014084A1
The use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia. Useful 5H-dibenz/b,f/azepine-5-carboxamide derivatives include compounds of the formula (I): where R1 is hydrogen, alkyl, halogenalkyl, aralkyl, cycloa...  
WO/2011/013646A1
Disclosed is a pharmaceutical product for prevention and treatment of sporadic amyotrophic lateral sclerosis, which contains, as an active ingredient, a substance that is selected from the group consisting of (a) leucomycins and oleandom...  
WO/2011/013470A1
Disclosed is an autoantibody production inhibitor which can inhibit an autoantibody specifically and can prevent or treat autoantibody autoimmune diseases effectively. The autoantibody production inhibitor is characterized by comprising,...  
WO/2011/013699A1
A foreign substance introduction method, which comprises the steps of: preparing a foreign substance introduction construct comprising a carrier peptide fragment and a foreign substance of interest bound to the N-terminal side and/or the...  
WO/2011/010682A1
Disclosed is a sterol derivative, which has an effect of promoting the proliferation of nerve stem cells, or a pharmaceutically acceptable salt of the same. Specifically disclosed is a sterol derivative represented by general formula (I)...  
WO/2011/011252A1
Nutritional compositions and methods of using the nutritional compositions with exercise to attenuate the loss of functional status are provided. In a general embodiment, the present disclosure provides a nutritional composition includin...  
WO/2011/009075A2
The present disclosure provides biologically active deuterated 2,4-pyrimidinediamine compounds and prodrugs thereof, compositions comprising the deuterated compounds, intermediates and methods for synthesizing the deuterated compounds an...  
WO/2011/007794A1
The present invention is directed to improve the usefulness of zeolite and sericite in various medical fields. To achieve this purpose, a composition for medical or medical assisting uses, which contains zeolite and sericite, is provided...  
WO/2011/007866A1
Disclosed are an agent which is capable of correcting splicing disorders of myotonic dystrophy, and a use of the agent. Specifically disclosed is an agent for treatment of myotonic dystrophy, which contains a compound the medicinal effec...  
WO/2011/003129A1
The present invention relates to a method for slowing the development of mammalian organ, tissue and cellular damage and death by using a persistent sodium current blocker (or a pharmaceutically acceptable salt or derivative thereof). Th...  
WO/2011/004911A1
Provided is a method of producing a skeletal muscle progenitor cell using a pluripotent stem cell, particularly an iPS cell, the method comprising the step 1) of culturing a pluripotent stem cell under serum-free conditions, and in the p...  
WO/2011/002525A1
The present invention relates to methods and agents useful for treating muscular dystrophy. Methods and agents for treating various physiological and pathological features associated with muscular dystrophy are also provided.  
WO/2011/002520A2
Componds and pharmaceutical compositions are provided that inhibit the activity of poly ADP- ribose synthetase (PARP). Such compounds are useful in the treatment of various diseases, conditions and injuries such as stroke, myocardial inf...  
WO/2011/002520A3
Componds and pharmaceutical compositions are provided that inhibit the activity of poly ADP- ribose synthetase (PARP). Such compounds are useful in the treatment of various diseases, conditions and injuries such as stroke, myocardial inf...  
WO/2010/151042A3
The present invention relates to a composition which contains Schizandra chinensis Baillon and Chaenomeles sinensis extracts as active ingredients for alleviating muscle fatigue and muscle pain or for enhancing exercise capability. The c...  
WO/2010/151840A2
This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations.  
WO/2010/151042A2
The present invention relates to a composition which contains Schizandra chinensis Baillon and Chaenomeles sinensis extracts as active ingredients for alleviating muscle fatigue and muscle pain or for enhancing exercise capability. The c...  
WO/2010/148010A1
The present invention provides chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides and an internalising moiety, wherein, the moiety can be an antibody, and is preferably monoclonal antibody 3E10, a functional variant or a...  
WO/2010/147226A1
Provided is a compound having a serotonin 5-HT2c receptor activating action, useful for lower urinary tract conditions, obesity and cancer. A compound represented by the formula (I0): wherein each symbol is as defined in the specificatio...  
WO/2010/146622A1
Provided are drugs, external preparations and cosmetics having an effect of inhibiting NFAT signal, an effect of inhibiting calcineurin and an effect of promoting hair growth. An NFAT signal inhibitor which comprises as the active ingred...  
WO/2010/140685A1
Disclosed is an amplifier for hematopoietic stem cells and/or hematopoietic progenitor cells which is useful for treating various diseases and for improving the efficiency of transferring a gene into hematopoietic stem cells in gene ther...  
WO/2010/136508A3
The present invention describes an antigen-binding construct comprising a first agent which binds to a stem cell specific marker molecule and a second agent which binds to a tissue specific marker molecule. In particular, the invention d...  
WO/2010/137349A1
Disclosed is a compound which enhances the activity of neurotrophic factors and exerts a protective action on nerve cells. Specifically disclosed is a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a s...  
WO/2010/137350A1
Disclosed is a compound which enhances the activity of neurotrophic factors and exerts a protective action on nerve cells. Specifically disclosed is a compound represented by formula (Ia) or (Ib), a pharmaceutically acceptable salt there...  
WO/2010/138670A3
Disclosed herein are thiocolchicine derivatives suitable for use as muscle relaxants, methods of making the derivatives, and compositions comprising the derivatives.  
WO/2010/136508A2
The present invention describes an antigen-binding construct comprising a first agent which binds to a stem cell specific marker molecule and a second agent which binds to a tissue specific marker molecule. In particular, the invention d...  
WO/2010/138670A2
Disclosed herein are thiocolchicine derivatives suitable for use as muscle relaxants, methods of making the derivatives, and compositions comprising the derivatives.  
WO/2010/137351A1
The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tet...  
WO/2010/132982A1
It is reported herein that certain muscle diseases and conditions, including forms of muscular dystrophy, are characterized by impaired insulin-dependent signaling in the muscle tissue, in essence, a form of insulin resistance. The prese...  
WO/2010/134047A3
The present invention relates to a pharmaceutical solution comprising isotretinoin or salts thereof. The present invention further relates to the processes for preparing such compositions.  
WO/2010/131382A1
Disclosed is a muscle repair promoter for local administration, which comprises a granulocyte-colony stimulating factor (G-CSF) as an active ingredient. The muscle repair promoter can exhibit the efficacy thereof at a small dose particul...  
WO/2010/130799A3
The present invention relates to a batch method for impregnating a nonporous polymer pharmaceutical carrier with an active substance, characterised in that said method includes the following consecutive steps: a) mixing the active substa...  
WO/2010/131712A1
Disclosed are a therapeutic pharmaceutical agent for diseases associated with the decrease in the function of GNE protein, a food composition, and a food additive. The therapeutic pharmaceutical agent is characterized by comprising a com...  
WO/2010/130799A2
The present invention relates to a batch method for impregnating a nonporous polymer pharmaceutical carrier with an active substance, characterised in that said method includes the following consecutive steps: a) mixing the active substa...  
WO/2010/129406A3
The present invention relates to use of the interaction of myostatin with the activin type II receptors, and more specifically to use of soluble ACVR2 to increase muscle growth in a subject. As such, methods of increasing muscle mass in ...  
WO/2010/129273A2
The present invention relates to the use of butaclamol and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.  
WO/2010/128243A1
The present invention relates to a method for preparing a concentrated spinach extract in a liquid or dry form and having a polyphenol titer greater than or equal to 50%, including a step of purifying a raw spinach extract in a liquid fo...  
WO/2010/129273A3
The present invention relates to the use of butaclamol and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.  
WO/2010/129406A2
The present invention relates to use of the interaction of myostatin with the activin type II receptors, and more specifically to use of soluble ACVR2 to increase muscle growth in a subject. As such, methods of increasing muscle mass in ...  
WO/2010/125271A1
The invention relates to a gas mixture that contains nitrous oxide (N2O) for use as a breathable drug for the treatment of chronic pain in a mammal, in particular a pain from neuropathic, iatrogenic, dysfunctional or inflammatory origin,...  
WO/2010/124365A1
There are provided compositions and methods for modulating stem cell division decisions, in particular, division symmetry. It has been demonstrated that wnt7a acts through frizzled-7 receptor expressed on the surface of adult stem cells,...  

Matches 451 - 500 out of 15,685